Telomir Pharmaceuticals (NASDAQ:TELO) Issues Earnings Results, Beats Estimates By $0.04 EPS

by · The Cerbat Gem

Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04, FiscalAI reports.

Telomir Pharmaceuticals Stock Up 3.3%

NASDAQ:TELO traded up $0.04 during mid-day trading on Thursday, reaching $1.27. The company’s stock had a trading volume of 74,851 shares, compared to its average volume of 141,788. Telomir Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $3.10. The stock has a fifty day moving average of $1.32 and a 200-day moving average of $1.33. The firm has a market capitalization of $43.66 million, a PE ratio of -3.85 and a beta of -0.21.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TELO. Wall Street Zen raised Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Zacks Research raised Telomir Pharmaceuticals to a “hold” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Read Our Latest Report on TELO

Institutional Investors Weigh In On Telomir Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Marshall Wace LLP bought a new position in shares of Telomir Pharmaceuticals during the second quarter valued at approximately $95,000. Raymond James Financial Inc. raised its stake in Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after buying an additional 73,547 shares in the last quarter. Jane Street Group LLC purchased a new stake in Telomir Pharmaceuticals during the second quarter worth $62,000. XTX Topco Ltd purchased a new stake in Telomir Pharmaceuticals during the fourth quarter worth $53,000. Finally, Geode Capital Management LLC boosted its position in Telomir Pharmaceuticals by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after acquiring an additional 27,519 shares in the last quarter.

Telomir Pharmaceuticals Company Profile

(Get Free Report)

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.

Read More